乐普医疗注射用重组A型肉毒毒素获得药物临床试验批准

Core Viewpoint - Lepu Medical (300003) announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial of its self-developed injectable recombinant type A botulinum toxin [1] Group 1 - The approval of the clinical trial application for injectable recombinant type A botulinum toxin (LPJT-099/DP) signifies the company's strong and efficient R&D capabilities in the dermatology field [1] - This development enriches the company's product portfolio in dermatology, enhancing its core competitiveness in this niche market [1] - The progress in this research project supports the company's long-term development in the consumer healthcare market [1]